Actinium 225
No carrier added
IONETIX produces Actinium-225 in the Lansing, Michigan facility. Actinium 225 is a radioisotope used for treatment in targeted alpha therapy. Clinical trials have demonstrated the applicability of radiopharmaceuticals containing Act225 to treat various types of cancer including leukemia, prostate cancer and primary tumors.
Learn more about Alpha Therapy→
Ionetix Announces Start of Construction to add Second Cyclotron for Ac-225 Production at its Alpha Isotope Manufacturing Facility
Ionetix Corporation is pleased to announce the official project start to expand its Alpha Isotope Manufacturing facility. This project marks a significant milestone for Ionetix in establishing a robust supply platform that includes onsite redundancy of Ac-225 production, as well as scalable output capacity to support commercial activity.
View the press release→
Harness the power to deliver advanced radiopharmaceuticals
The time is now to partner with us to gain access to scarce diagnostics and therapeutic radiopharmaceuticals.
Get started now→